RxDoctor Payments Data

Amanda Foraker, APRN

Family Medicine · Alliance, OHNPI 1942871736

Payments from drug & device makers

$3,501in general payments, 2019–2025

Across 224 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$573
  • AbbVie$461
  • Pfizer$428
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$346
  • Novo Nordisk$249
  • AstraZeneca$226
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,42798%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,501 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$6,367
Medicare patients
42
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$25,240
JardianceEmpagliflozin12$12,196
MounjaroTirzepatide11$11,748
OzempicSemaglutide11$9,946
EliquisApixaban11$9,809
SymbicortBudesonide/Formoterol Fumarate13$4,581
Atorvastatin Calcium208$2,018
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide33$1,948
Albuterol Sulfate HfaAlbuterol Sulfate66$1,575
Levothyroxine Sodium180$1,561
Metoprolol Succinate73$1,378
Omeprazole114$1,279
Simvastatin112$901
Lisinopril117$895
Potassium Chloride33$878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$108$25,24024 claims
Boehringer IngelheimJardiance$13$12,19612 claims
Lilly USA, LLCMounjaro$573$11,74811 claims
Novo NordiskOzempic$249$9,94611 claims
PfizerEliquis$428$9,80911 claims
AstraZenecaSymbicort$226$4,58113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Alliance

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →